TLSA - Tiziana Life Sciences Ltd
About Tiziana Life Sciences Ltd (https://www.tizianalifesciences.com)
Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression. Another significant asset is anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody intended to mitigate IL6-induced inflammation and treat COVID-19 patients. Founded in 1998, Tiziana Life Sciences is based in London, United Kingdom.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Ivor R. Elrifi | Chief Executive Officer & Executive Director | – | $131,000 GBP |
| Gabriele Marco Antonio Cerrone | Founder & Executive Chairman | 1972 | – |
| Keeren Shah | Chief Operating Officer & Chief Financial Officer | 1976 | – |
| Napoleone Ferrara | Member of Scientific Advisory Board | 1957 | – |
| Richard K. Kim | Chief Medical Officer | 1971 | – |
| William Edward Tente | Chief Regulatory Officer | 1958 | – |